Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Publication | Open Access

DOI Full Paper Access

Citations

References

2009

Year

E.H. Tan, Janusz Rolski, Tomasz Grodzki, C. Schneider, U. Gatzemeier, Petr Zatloukal, Enrico Aitini, Giacomo Cartenì, H. Riska, Y H Tsai,

Annals of Oncology

Final ResultsCisplatin Versus DocetaxelMedicineBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerRadiologyHealth Sciences